NCT00108732: A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer |
|
|
| Completed | 2 | 50 | US | Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, PROSTVAC-F, rFowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, rV-TRICOM, Vaccinia-TRICOM, vaccinia-TRICOM vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin | National Cancer Institute (NCI) | Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer | 10/10 | 10/10 | | |
